Improvement of Quality of Life by Cannabinoids in Oncologic Patients (BEfindLichkeitsverbesserung Unter CANnabinoid-ExtrakTen Bei Onkologischen Patienten)

The goal is to explore whether the application of cannabis extract Avextra 10/10 solution is suitable to contribute to an improvement in the symptom burden and well-being of oncological palliative care patients. The primary objective of the study is to demonstrate the improvement in global symptom burden in the intervention arm compared to the placebo control group over a period of 12±2 days, as measured by a percentage change in the value of the Edmonton Symptom Assessment System total symptom distress score (ESAS TSDS) at baseline and after 12±2 days.

Start Date08 Apr 2024

Sponsor / Collaborator

Universitätsklinikum Schleswig-Holstein

[+1]

RBR-33f4vgr / RecruitingPhase 3IIT

Evaluation of the effectiveness of the use of Cannabinoids in controlling Neuropathic Pain in Low Back Pain

Start Date17 Jan 2024

Sponsor / Collaborator-

100 Clinical Results associated with Cannabinoids

100 Translational Medicine associated with Cannabinoids

100 Patents (Medical) associated with Cannabinoids

7,491

Literatures (Medical) associated with Cannabinoids

01 Apr 2025·Neural Regeneration Research

Astrocytes, reactive astrogliosis, and glial scar formation in traumatic brain injury

Article

Author: Ramos, Alberto Javier ; Cieri, María Belén

Traumatic brain injury is a global health crisis, causing significant death and disability worldwide. Neuroinflammation that follows traumatic brain injury has serious consequences for neuronal survival and cognitive impairments, with astrocytes involved in this response. Following traumatic brain injury, astrocytes rapidly become reactive, and astrogliosis propagates from the injury core to distant brain regions. Homeostatic astroglial proteins are downregulated near the traumatic brain injury core, while pro-inflammatory astroglial genes are overexpressed. This altered gene expression is considered a pathological remodeling of astrocytes that produces serious consequences for neuronal survival and cognitive recovery. In addition, glial scar formed by reactive astrocytes is initially necessary to limit immune cell infiltration, but in the long term impedes axonal reconnection and functional recovery. Current therapeutic strategies for traumatic brain injury are focused on preventing acute complications. Statins, cannabinoids, progesterone, beta-blockers, and cerebrolysin demonstrate neuroprotective benefits but most of them have not been studied in the context of astrocytes. In this review, we discuss the cell signaling pathways activated in reactive astrocytes following traumatic brain injury and we discuss some of the potential new strategies aimed to modulate astroglial responses in traumatic brain injury, especially using cell-targeted strategies with miRNAs or lncRNA, viral vectors, and repurposed drugs.

01 Jan 2025·JOURNAL OF ETHNOPHARMACOLOGY

Cannabidiol finds dihydrocannabidiol as its twin in anti-inflammatory activities and the mechanism

Article

Author: Shi, Qiandai ; Xia, Yongmei ; Guo, Maoyue ; Wu, Qi ; Wang, Qiqi ; Zhu, Song

ETHNOPHARMACOLOGICAL RELEVANCE:

The hemp (cataloged at the "Medicinal Plant Names Services" as Cannabis sativa L.) extracts, cannabinoids have been used for centuries in Southeast Asia as folk medicines and now authorized by about 50 countries for application in medicine, health care products and cosmetics. As the most consumed cannabinoid, cannabidiol (CBD) has been recognized due to its various bioactivities, including anti-inflammatory and antibacterial properties.

AIMS OF THE STUDY:

The utilization of CBD is limited due to its potential conversion to psychoactive Δ9-tetrahydrocannabinol in strong acidic environment, demanding to excavate safer alternatives with clarified bioactivities. Yet the anti-inflammatory and antibacterial properties of CBD still remain unknown, in both of the performances and the corresponding mechanisms. Previously, a synthetic CBD analogue, H2CBD (Dihydrocannabidiol) was found to be effective as CBD does towards some antioxidantive activities and mouse seizure mitigation. Therefore, it is wondering if H2CBD also acted similarly as CBD does in the aspect of anti-inflammatory performance and mechanism, and the safety.

MATERIAL AND METHODS:

The anti-inflammatory properties of CBD and H2CBD were revealed with enzymatic assays, proteins denaturation and lipopolysaccharide (LPS) stimulated RAW264.7 cells model, with epigallocatechin gallate (EGCG) as the positive control. Their anti-inflammatory mechanism was revealed with ELISA and Western blot assay. The antibacterial properties of CBD and H2CBD were also investigated towards E. faecalis and B. cereus along with their synergistic effect with commercial antibiotics.

RESULTS:

CBD and H2CBD exhibited almost same (P > 0.05) performance in all the assayed anti-inflammatory properties, yet their anti-inflammatory efficiencies positively correlated to their antioxidantive activity. Moreover, both of CBD and H2CBD presented anti-inflammation to LPS stimulated RAW264.7 cells through NF-κB and AKT pathway. Furthermore, CBD and H2CBD also supplied strong and very similar (P > 0.05) antibacterial activities, comparable to tetracycline in same dose and strength. The erythrocyte hemolytic assay indicates CBD and H2CBD possessing the same safety. All the combinations of H2CBD with other cannabinoids or antibiotics present no antagonism against the bacteria, but nice synergistic or additive effect in some cases.

CONCLUSION:

CBD and H2CBD presented very similarly in all the assayed anti-inflammatory performances, undergoing same inflammatory mechanism with NF-κB and AKT pathway; they also expressed similar antibacterial activity, like twins. These findings will supply CBD a sustainable, safer and economic alternative with same excellent performances.

01 Dec 2024·Biological trace element research

Determination of Toxic Elements in Cannabinoid and Opioid Drugs and Their Impact on Addicts’ Health: A Comparative Study

Article

Author: Unar, Ahsanullah ; Talpur, Farah Naz ; Afridi, Hassan Imran ; Sahito, Oan Muhammad ; Ataya, Farid Shokry ; Ali, Naveed ; Fouad, Dalia ; Bashir, Muhammad Sohail ; Alsawalha, Laila

Drug addiction is associated with significant health risks, including cardiovascular complications, cancer, and mental disorders. Illicit drugs, such as cannabinoids and opioids, including prescription medications, are widely consumed and have profound health consequences. Understanding the health effects of the toxic elements in these substances is critical for overdose prevention and effective recovery strategies. This study aimed to determine toxic elements, including arsenic (As), cadmium (Cd), mercury (Hg), and nickel (Ni), in cannabinoid and opioid drugs and in biological samples (whole blood, scalp hair, and serum) from 311 male drug abuse patients aged 15-60 years with a history of drug abuse. The participants were categorized into three age groups. The comparative analysis involved 113 reference subjects of the same age groups. The sample preparation employed microwave-assisted acid digestion, and the toxic elements were quantified using atomic absorption spectrophotometry. Accuracy was ensured using certified reference materials for hair, whole blood, and serum samples. Drug-addicted subjects had significantly higher concentrations of toxic elements (arsenic, cadmium, mercury, and nickel) in biological samples than referent subjects (p > 0.001). Elevated levels of these toxic elements may increase susceptibility to infections, possibly due to malnutrition, drug-related effects, and additional contaminants. These findings necessitate further studies to explore the long-term health outcomes, potential treatment options, and broader socioeconomic impacts of substance abuse. This study serves as a baseline for future research in this critical public health field.

348

News (Medical) associated with Cannabinoids

31 Oct 2024

·www.globenewswire.com

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. The DRDC conducted an additional control study to achieve optimal dosing. The research study is progressing and is now expected to be completed with final results by the end of calendar 2024. The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and explore its potential for traumatic brain injury caused by concussive or explosive forces and viral infections. Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death. Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam. Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com. For more information, please contact: Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: mfrank@revivethera.comWebsite: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the year ended June 30, 2024 ("MD&A"), dated October 25, 2024, which is available on the Company's profile at www.sedarplus.ca.

Orphan DrugFast TrackClinical Study

24 Oct 2024

·www.prnewswire.com

Curaleaf Report: Online and unregulated cannabis poses serious health risks with mould, lead, and synthetic cannabinoids detected

Illegal cannabis sales through unregulated online retailers have increased 50% in past two years 73% of the illegal online market is driven by those seeking relief from health conditions Tests show illegal cannabis in the UK contains harmful substances such as mould, lead, and synthetic cannabinoids, posing serious health threats to consumers Curaleaf International calls for public education, stronger enforcement, and regulatory reform to tackle the illegal market and safeguard consumers LONDON, Oct. 24, 2024 /PRNewswire/ -- Curaleaf International, a global leader in medical cannabis, is urging the UK government to take immediate action against the rapidly growing online illicit cannabis market, which is allowing street cannabis to be sold from unregulated and unpoliced websites and platforms. Curaleaf's latest report reveals that illegal online cannabis sales via the open and dark web have risen by 50% in the past two years, and increased by 67% across open web retailers. This is largely being driven by consumers buying illegal cannabis to seek relief from health conditions like chronic pain, insomnia, and anxiety (73% of online purchasers) - many of whom could be eligible for legally prescribed medical cannabis. Curaleaf's report, developed in partnership with Manchester Metropolitan University, also found that illegal cannabis is often contaminated with dangerous substances such as mould, lead, and synthetic cannabinoids, posing severe health risks to the 1.8 million people in the UK who use the product to self-treat medical conditions. This unregulated market not only endangers public health but also undermines the legal, medical cannabis industry, which adheres to strict quality and safety standards. Despite dangers including respiratory issues, neurological damage, and increased risk of infection, one in five (17%) cannabis consumers mistakenly believe illegal cannabis is safer than regulated medical cannabis or don't know the difference, highlighting an urgent need for public education to tackle the illicit market and safeguard consumers. Curaleaf International advocates for a holistic reform strategy that encompasses: Tightened Regulation of Illegal Channels: Strengthening enforcement against unlicensed online sales and dark web activity to protect consumers from unregulated and potentially dangerous products. Public Awareness Initiatives: Launching comprehensive campaigns to educate the public on the risks associated with unregulated cannabis products and the advantages of the existing legal medical cannabis market. These campaigns will ensure patients make informed choices based on reliable information about regulated medical cannabis, which meets stringent safety and quality standards, unlike illicit products. Policy Changes to Improve Patient Access to Medicine: Simple regulatory and policy changes could significantly improve patient access to medical cannabis. For instance, enabling electronic prescribing of cannabis medicines would reduce the bureaucracy imposed on doctors and improve the efficiency of medicine dispensing. Expanded Research into Medical Cannabis: Promoting further clinical research to unlock the full therapeutic potential of cannabis. As a leader in the industry, Curaleaf International is already pioneering studies to advance the understanding of how medical cannabis affects patients with a range of diagnosed medical conditions, where other treatments have not provided relief. Juan Martinez, Head of Curaleaf International, stated: "While the online market for illicit cannabis is growing year on year and remains completely unregulated, the UK already has a legal medical cannabis market in place, which adheres to rigorous safety and quality standards. Our research has found alarmingly high levels of contamination in illegal cannabis, putting consumers' health at serious risk. If the UK government is truly committed to safeguarding public health and supporting legitimate businesses, it must do more to improve patient access to regulated medical cannabis and enforce stricter regulations on illegal sales. This includes educating the public on the benefits of regulated cannabis products and enhanced policing of internet search engines and service providers. By curbing the illicit market and expanding access to legal, regulated options, we can better protect vulnerable individuals and dismantle illegal operations." Boris Jordan, Chairman and CEO at Curaleaf Inc, added: "The findings in this new report echo our concerns across the globe, and highlight serious risks to patients in the UK. Similar testing done previously in the US found contaminated products in illegal dispensaries, and this is an issue that weighs on all of us in the industry. Without controlled and legal access to tested, regulated cannabis, patients and consumers are left vulnerable to extreme health risks. Lawmakers around the world must act now to enforce laws against the illicit market and widen access to legal, regulated cannabis products." About Curaleaf International Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis. Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler; and the EU-GMP producer Northern Green Canada. Curaleaf International is part of Curaleaf Holdings, Inc., a publicly listed business and the world's largest cannabis company. Contact: Iskander Javed [email protected] SOURCE Curaleaf International WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

08 Oct 2024

·www.globenewswire.com

Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases

The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral cannabinoid formulation for managing the symptoms of patients suffering from neurodegenerative diseases such as ALS, Alzheimer’s Disease and Parkinson’s Disease.NEUROBIS is the second Phase 2 clinical trial supported by Avextra.NEUROBIS is one of the few randomised, placebo controlled, double-blind trial with a Cannabis-based medicine to be conducted at multiple sites in Italy and a study of this robust scientific nature aligns perfectly with Avextra’s clinical plan.The study is funded by a grant from the Italian Ministry of Health signifying the support of regulators in gathering of clinical evidence for Cannabis-based medicines. BENSHEIM, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avextra AG (“Avextra” or the “Company”), a leading European manufacturer and developer of Cannabis-based medicines located in Germany, is proud to announce that both the Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral formulation in managing the symptoms of patients suffering from Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease and Parkinson’s Disease. The study, being conducted under the name NEUROBIS, is one of the few randomised, placebo controlled, double-blind trials to be conducted with a Cannabis-based medicine at multiple sites in Italy. A study of this robust scientific nature aligns perfectly with Avextra’s clinical plan. Avextra is partnering with the sponsor of NEUROBIS, the AOU Maggiore della Carità in Novara, Italy for a second company-supported Phase II clinical trial. The principal investigator is Prof. Dr. Letizia Mazzini, a Neurologist with over thirty years of experience in clinical research and Director of the Neurology Division at AOU Maggiore della Carità as well as Director of the ALS Regional Expert Centre at Department of Translational Medicine at the University of Piemonte Orientale. The study was funded by the Bando Ricerca Finalizzata through a grant from the Italian Ministry of Health as part of the National Health Research Program and will be conducted across two sites over a 36-month period. Preclinical studies and anecdotal evidence suggest that a specific CBD to THC ratio may play a role in managing symptoms such as pain, sleep deficiency and psychological stress for patients suffering from neurodegenerative conditions such as Alzheimer’s, Parkinson’s and Multiple Sclerosis. Avextra is committed to supporting and conducting clinical trials with the objective of developing safe, effective and regulatory approved medicines for patients where available treatment options fall short. Both the approval and the funding of NEUROBIS signify the supportive stance on the part of European regulatory bodies for gathering robust clinical evidence for Cannabis-based medicines. "We are excited to support a second Phase II clinical trial NEUROBIS in partnership with a leading university hospital in Italy, the AOU Maggiore della Carità Novara," said Dr. Bernhard Babel, CEO, at Avextra. "With two active Phase II clinical trials in BELCANTO in Germany and NEUROBIS in Italy, Avextra is uniquely positioned with the necessary skills and capabilities to design clinical trials and develop pharmaceutical IP with Cannabis-based medicines with the potential to improve patient’s quality of life." "At our hospital, which is a reference centre for many neurodegenerative diseases, we observe an increase in the number of individuals affected by Dementia, Parkinson’s Disease and ALS who require help with their symptoms. It is imperative to increase disease awareness and availability of treatment options to address these patient needs. As such we are grateful for the support of Avextra with their excellent clinical team and patient-centred approach," added Prof. Letizia Mazzini, Principal Investigator for NEUROBIS. NEUROBIS is one component of Avextra’s larger clinical plan to gather the robust evidence to support use of its unregistered products in specific indications as it undergoes development of EMA-Registered Cannabis-based Medicines. The company is dedicated to working in collaboration with the medical community, regulators and other stakeholders to drive evidence-based innovation forward. About Avextra AGAvextra is one of Europe’s leading vertically-integrated medical cannabis operators focused on the development and production of regulator-approved medicines. Founded in 2019 and based out of Germany, the company works in close collaboration with doctors and pharmacists and researchers to develop and produce innovative cannabis-based medicines. Avextra controls the entire value chain – from cultivation in Portugal to EU-GMP certified extraction and manufacturing in Germany. Avextra operates across continental Europe through an expansive distribution network of multiple channels and strategically developed assets for these key markets. Learn more at avextra.com and stay up to date at LinkedIn: LinkedIn.com/company/avextra-ag/

Phase 2Drug Approval

100 Deals associated with Cannabinoids

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 1	US	Cannabis Bioscience International Holdings, Inc.	20 Mar 2024
Alzheimer Disease	IND Approval	IT	Avextra Pharma GmbH	08 Oct 2024
Amyotrophic Lateral Sclerosis	IND Approval	IT	Avextra Pharma GmbH	08 Oct 2024
Parkinson Disease	IND Approval	IT	Avextra Pharma GmbH	08 Oct 2024
Brain Cancer	Preclinical	AU	Zelira Therapeutics Ltd.	24 Sep 2024
Brain Cancer	Preclinical	AU	Telethon Kids Institute	24 Sep 2024
Pancreatic Cancer	Preclinical	AU	Zelira Therapeutics Ltd.	24 Sep 2024
Pancreatic Cancer	Preclinical	AU	Curtin University	24 Sep 2024
Pelvic Inflammatory Disease	Preclinical	GB	Viramal Ltd.	23 Sep 2024
Breast Cancer	Preclinical	CA	Andira Medicine, Inc.Startup	25 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CRD42023479375 (ESMO2024)	Not Applicable	Cancer Pain	-	Cannabinoids	gayyvqiosz(pznmxshgme) = rxtxbkvwie tnjljdzdnp (xektfcevll, -0.65 to 0.75) View more	Positive	15 Sep 2024
NCT03782402 (CTgov)	Phase 2	Peripheral Nervous System Diseases	12	Cannabinoids (Placebo Cannabinoids)	sjsceeizjw(oggfpakzvl) = yrstysildb dwieoqukae (uacsxgfzvi, bmlqltbopo - uxjokosuga) View more	-	26 Jan 2023
				Cannabinoids (Cannabinoids (THC and CBD))	glbadixmgu(fspvyfcpda) = nshcwoktgr mhjaulctiy (vxzvtqbvgj, iapsdpastx - bobwwzwsrm) View more
EULAR2022	Not Applicable	Arthritis, Psoriatic	-	Cannabinoid	xybjjberna(vcfddikcry) = 17.5% of patients with RA using cannabinoids reported side effects not leading to cessation qwshimlrvo (rzfucctikh )	-	01 Jun 2022
ISC2022	Not Applicable	Ischemic stroke	256	Cannabinoid positive	dzqfysjirr(illobynxgu) = iyftchpatp qhvfnhkzmu (vmjunhsbhf )	-	01 Feb 2022
				Cannabinoid negative	dzqfysjirr(illobynxgu) = bkxqlhuklg qhvfnhkzmu (vmjunhsbhf )
ASN2020	Not Applicable	Kidney Tubular Necrosis, Acute	-	Synthetic cannabinoids (SC)	wgqhhnxirl(ojorynzdbr) = A renal biopsy showed acute tubular injury with tubular dilatation, cytoplasmic simplification and vacuolization (image) ozezvayvtj (amstabhcnq ) View more	-	19 Oct 2020
Pubmed \| Drug Test Anal	Not Applicable	-	-	Cannabinol (CBN)	fentduvzjf(wibjfadgtr) = xjxqfgxaou lxsfqfwskb (wjlchfbzzj )	-	01 Jun 2015
				11-nor-9-carboxy-THC (THCCOOH)	tkvnekweiq(hermsyxjxd) = cgrhzqfmrm horupepkiy (rimgnvlxbf )
ISRCTN62942668 (CUPID, Pubmed \| Health Technol Assess)	Phase 3	Brain Diseases \| Multiple Sclerosis	498	Δ(9)-tetrahydrocannabinol (Δ(9)-THC)	ycyyalzhvo(vkrdnxgxau): hazard ratio = 0.92 (95% CI, 0.68 - 1.23)	-	01 Feb 2015
				Placebo
Pubmed \| Subst Abus	Not Applicable	-	-	Synthetic Cannabinoids	pwygpajcka(ydujsblyzm) = ynawposqcu vxxgyjussv (qbxykdkmla )	-	01 Jan 2015
AAN2014	Not Applicable	Muscle Spasticity	36	cannabinoids	rhclwiyxji(vhselxvchd) = xosbnlgswv whipmpfndh (lngzsaoeye )	-	08 Apr 2014
EULAR2011	Not Applicable	Musculoskeletal Diseases	218	Cannabinoids	mecjixqyud(fctrzecpgx): P-Value = 5.48 View more	-	25 May 2011
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cannabinoids

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation